Mesoblast Ltd (MSB) - Total Liabilities
Based on the latest financial reports, Mesoblast Ltd (MSB) has total liabilities worth AU$207.62 Million AUD (≈ $146.91 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mesoblast Ltd - Total Liabilities Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's total liabilities have evolved over time, based on quarterly financial data. See MSB net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Mesoblast Ltd Competitors by Total Liabilities
The table below lists competitors of Mesoblast Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Offcn Education Technology Co Ltd
SHE:002607
|
China | CN¥4.89 Billion |
|
Guangzhou Risong Intelligent Technology Holding Co Ltd
SHG:688090
|
China | CN¥940.80 Million |
|
Omnicell Inc
NASDAQ:OMCL
|
USA | $742.91 Million |
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
USA | $4.39 Billion |
|
China Yuchai International Limited
NYSE:CYD
|
USA | $14.75 Billion |
|
Trust Alliance Information Development Inc Ltd Shanghai
SHE:300469
|
China | CN¥853.02 Million |
|
Guangdong Tonze Electric Co Ltd
SHE:002759
|
China | CN¥2.58 Billion |
|
United Parks & Resorts Inc
NYSE:PRKS
|
USA | $3.05 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Mesoblast Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MSB stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mesoblast Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mesoblast Ltd (2005–2025)
The table below shows the annual total liabilities of Mesoblast Ltd from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$187.24 Million ≈ $132.48 Million |
-0.82% |
| 2024-06-30 | AU$188.80 Million ≈ $133.59 Million |
+12.66% |
| 2023-06-30 | AU$167.58 Million ≈ $118.57 Million |
+1.50% |
| 2022-06-30 | AU$165.10 Million ≈ $116.82 Million |
+1.09% |
| 2021-06-30 | AU$163.32 Million ≈ $115.56 Million |
-11.37% |
| 2020-06-30 | AU$184.28 Million ≈ $130.39 Million |
+7.72% |
| 2019-06-30 | AU$171.06 Million ≈ $121.04 Million |
+16.82% |
| 2018-06-30 | AU$146.44 Million ≈ $103.61 Million |
+5.41% |
| 2017-06-30 | AU$138.92 Million ≈ $98.29 Million |
-10.87% |
| 2016-06-30 | AU$155.86 Million ≈ $110.28 Million |
-61.85% |
| 2015-06-30 | AU$408.57 Million ≈ $289.09 Million |
+24.72% |
| 2014-06-30 | AU$327.60 Million ≈ $231.80 Million |
+29.26% |
| 2013-06-30 | AU$253.45 Million ≈ $179.33 Million |
+4.90% |
| 2012-06-30 | AU$241.61 Million ≈ $170.95 Million |
-2.34% |
| 2011-06-30 | AU$247.41 Million ≈ $175.06 Million |
+15406.41% |
| 2010-06-30 | AU$1.60 Million ≈ $1.13 Million |
+34.64% |
| 2009-06-30 | AU$1.19 Million ≈ $838.50K |
-24.65% |
| 2008-06-30 | AU$1.57 Million ≈ $1.11 Million |
+125.04% |
| 2007-06-30 | AU$698.90K ≈ $494.52K |
-84.19% |
| 2006-06-30 | AU$4.42 Million ≈ $3.13 Million |
+100.61% |
| 2005-06-30 | AU$2.20 Million ≈ $1.56 Million |
-- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more